home / stock / cansd / cansd news
(NewsDirect) Willow Bioscience CEO Dr Chris Savile joined Steve Darling from Proactive to share a significant development. The company has unveiled a noteworthy partnership with a Nasdaq-listed biopharmaceutical company, with a shared objective of forging precise and efficient manufacturi...
(NewsDirect) Willow Bioscience CEO Dr Chris Savile joined Steve Darling from Proactive to announce a significant collaboration agreement between Willow Biosciences and Suanfarma. The partnership is focused on optimizing cell line productivity for manufacturing a high-volume anti-infec...
(NewsDirect) Willow Bioscience CEO Dr Chris Savile joined Steve Darling from Proactive to announce some significant developments within the company. Willow Bioscience specializes in the production of ursodeoxycholic acid (UDCA), a vital pharmaceutical ingredient with extensive applica...
(NewsDirect) Willow Bioscience CEO Dr Chris Savile joined Steve Darling from Proactive to announce a groundbreaking development in the pharmaceutical industry. Savile shared the company's achievement in creating a cost-effective process for producing corticosteroids using their innova...
(NewsDirect) Willow Bioscience CEO Dr Chris Savile joined Steve Darling from Proactive to share news the company has embarked on a major strategic shift, focusing its commercial efforts on the BioOxi platform. To assist in this transition, Willow Biosciences has engaged an advisor to expl...
(NewsDirect) Willow Bioscience CEO Dr Chris Savile joined Steve Darling from Proactive to share news the company has agreed to a Master Services Agreement with an innovative biotech company with the focus on age-related diseases. This partnership will see the company develop precision fer...
News, Short Squeeze, Breakout and More Instantly...
Willow Biosciences Company Name:
CANSD Stock Symbol:
OTCMKTS Market:
(NewsDirect) Willow Bioscience CEO Dr Chris Savile joined Steve Darling from Proactive to share a significant development. The company has unveiled a noteworthy partnership with a Nasdaq-listed biopharmaceutical company, with a shared objective of forging precise and efficient manufacturi...
(NewsDirect) Willow Bioscience CEO Dr Chris Savile joined Steve Darling from Proactive to announce a significant collaboration agreement between Willow Biosciences and Suanfarma. The partnership is focused on optimizing cell line productivity for manufacturing a high-volume anti-infec...
(NewsDirect) Willow Bioscience CEO Dr Chris Savile joined Steve Darling from Proactive to announce some significant developments within the company. Willow Bioscience specializes in the production of ursodeoxycholic acid (UDCA), a vital pharmaceutical ingredient with extensive applica...